RE:As NCIB tapers off...Yes... we'll see how it goes. Always hard to predict price movements.
It's also possible they keep on buying, right?
Lots of positive momentum in my opinion as well.
---
Samira on growth (Q3 earnings call): It’s coming from a whole bunch of different places. So we have in our oncology product portfolio, I look at products like Lenvima, Akynzeo, Trelstar, they all continue to grow. We will be launching Minjuvi, which is coming earlier than we originally expected. We are launching Imvexxy, also in Canada next year.
And all of those products are going to continue to provide growth. We also have Cresemba in our infectious disease portfolio, which is continuing to grow in all of our markets.
And we’re going to continue to build a pipeline and advance the pipeline that we have.
---
But 2025 is where we truly get busy with launches for the first time. 9 products have launches expected for 2025 currently, and that list may still grow.
And as always, any new deal can have a significant impact as well. But the team seems to be in place, the platform is built, current portfolio grows, lots of new launches coming up, and still plenty of capital to use for whatever they may run into. We're developing scale and we're now starting to see the effects in terms of revenue growing but operating expenses staying flattish.